Replies to post #203168 on Biotech Values

[DewDiligence]

how do you think this will impact Opdivo NSCLC combination therapies?

In first-line NSCLC, today's news may retard the progress of Opdivo-based combination therapies to some degree, but it's certainly not a death blow.